FDA Will Review Translarna for DMD
PTC Therapeutics announced that the FDA will review its investigational drug ataluren (brand name Translarna) for the treatment of some forms of DMD.
An expression of the live unlimited spirit, stories and voices of the MDA community
PTC Therapeutics announced that the FDA will review its investigational drug ataluren (brand name Translarna) for the treatment of some forms of DMD.
For this latest round of awards, MDA reviewed 187 applications and had sufficient funds to approve funding for approximately 15 percent of them — 29 grants with a total funding commitment of more than $7 million.
Colin Batty will be running with MDA Team Momentum in the Boston Marathon to raise funds in honor of family members who live with CMT.
Fourteen-year-old Kentucky native Gabrielle’s favorite subject is geography, which is appropriate when you have an insatiable desire to travel. Gabrielle, who has spinal muscular atrophy (SMA) Type 2, has already seen a great deal of the world, including Europe, the Caribbean and the western United States. This year, Gabrielle is featured as a “Shamrockstar” on platinum MDA Shamrocks at retailers across the country, a country that Gabrielle has seen extensively in her travels with her family.
Following the approval of three drugs in six months, new MDA grants push for more progress By Grace Pavlath, Ph.D., MDA Senior Vice President & Scientific Program Director What are the effects of steroids on muscle repair in patients with Duchenne muscular dystrophy (DMD)? How can gene therapy impact people with Charcot-Marie-Tooth disease (CMT)? Will . . .
As policy makers are considering various options to modify or replace the Affordable Care Act (ACA), MDA is working to ensure that individuals and families affected by chronic, serious and life-threatening diseases maintain health care access and coverage.
Inspired by a beloved community member with ALS, this Illinois dodgeball tournament is good fun for a good cause.
Many families whose children have spinal muscular atrophy (SMA) endure a long and difficult diagnostic odyssey. This may soon change, however, based on recommendations MDA recently made with a coalition of partners that SMA should be added to the list of conditions newborns are screened for at birth in the United States.
The Labbadia family never wanted to need an MDA Care Center, but when son Brendan was diagnosed with Duchenne muscular dystrophy, they found that their team at Nemours Children’s Hospital in Orlando, Fla., including pediatric neurologist Dr. Richard Finkel, was the one bright spot of an otherwise devastating journey.
Over the past 35 years, the MDA Shamrocks program has raised more than $300 million to help save and improve the lives of families living with muscular dystrophy. Get to know Maya, who graces the 2017 green MDA Shamrock.
Sign up for MDA news & updates.